Thesis
Dexfenfluramine, Fenfluramine an Phentermine for the Treatment of Morbid Obesity
Washington State University
Master of Nursing (MN), Washington State University
05/1998
Handle:
https://hdl.handle.net/2376/4003
Abstract
In the U.S., obesity is the second leading cause of preventable death. This paper examined research regarding weight reduction efficacy, side-effects and cost/benefit analysis of dexfenfluramine (Redux), fenfluramine (Pondimin) and phentermine (Ionamin, Fastin). All are schedule IV drugs. Several studies concluded these medications decreased cardiovascular risk factors. Increased risk of PPH is linked to use >3 months. 10%-15% weight loss occurs in first six months of therapy. Common side effects are dry mouth, insomnia, diarrhea and lethargy. Careful patient screening is required before prescribing. The main goal of treatment is to promote weight loss and prevent weight regain. An informed consent form may be of value. Further study of the long-term efficacy and safety of these medications seems warranted.
Metrics
17 File views/ downloads
29 Record Views
Details
- Title
- Dexfenfluramine, Fenfluramine an Phentermine for the Treatment of Morbid Obesity
- Creators
- Linda Kay Torretta
- Contributors
- Lorna Schumann (Advisor)
- Awarding Institution
- Washington State University
- Academic Unit
- Research Projects, College of Nursing
- Theses and Dissertations
- Master of Nursing (MN), Washington State University
- Publisher
- Washington State University; Spokane, Washington
- Identifiers
- 99900590727501842
- Copyright
- http://creativecommons.org/licenses/by-nc-sa/3.0/us; Creative Commons Attribution-NonCommercial-ShareAlike 3.0 United States (CC BY-NC-SA 3.0 US)
- Language
- English
- Resource Type
- Thesis